152 related articles for article (PubMed ID: 18159051)
21. [Denosumab efficient against osteoporosis. A biological drug gives new possibilities to treat a public disease].
Törring O
Lakartidningen; 2010 Mar 3-9; 107(9):574-5. PubMed ID: 20387753
[No Abstract] [Full Text] [Related]
22. Denosumab, osteoporosis, and prevention of fractures.
Kyrgidis A
N Engl J Med; 2009 Nov; 361(22):2189; author reply 2190-1. PubMed ID: 19950409
[No Abstract] [Full Text] [Related]
23. Denosumab (prolia) for postmenopausal osteoporosis.
Med Lett Drugs Ther; 2010 Oct; 52(1349):81-2. PubMed ID: 21045756
[No Abstract] [Full Text] [Related]
24. Preventing metastases to bone: denosumab or bisphosphonates?
Nanes MS
J Bone Miner Res; 2010 Mar; 25(3):437-9. PubMed ID: 20200989
[No Abstract] [Full Text] [Related]
25. New developments for treatment and prevention of bone metastases.
Body JJ
Curr Opin Oncol; 2011 Jul; 23(4):338-42. PubMed ID: 21519257
[TBL] [Abstract][Full Text] [Related]
26. Unravelling the role of denosumab in prostate cancer.
Aragon-Ching JB
Lancet; 2011 Mar; 377(9768):785-6. PubMed ID: 21353698
[No Abstract] [Full Text] [Related]
27. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.
Fizazi K; Lipton A; Mariette X; Body JJ; Rahim Y; Gralow JR; Gao G; Wu L; Sohn W; Jun S
J Clin Oncol; 2009 Apr; 27(10):1564-71. PubMed ID: 19237632
[TBL] [Abstract][Full Text] [Related]
28. Effect of RANKL-specific denosumab on osteoclast number and function: a potential friend or foe?
Tankó LB
Curr Opin Investig Drugs; 2007 Oct; 8(10):830-5. PubMed ID: 17907059
[TBL] [Abstract][Full Text] [Related]
29. Denosumab in postmenopausal women with low bone mineral density.
McClung MR; Lewiecki EM; Cohen SB; Bolognese MA; Woodson GC; Moffett AH; Peacock M; Miller PD; Lederman SN; Chesnut CH; Lain D; Kivitz AJ; Holloway DL; Zhang C; Peterson MC; Bekker PJ;
N Engl J Med; 2006 Feb; 354(8):821-31. PubMed ID: 16495394
[TBL] [Abstract][Full Text] [Related]
30. [New bone density conservation agents for osteoporosis under research and development: Anti-RANKL antibody].
Wada S; Fukawa T; Kamiya S
Nihon Rinsho; 2007 Nov; 65 Suppl 9():459-62. PubMed ID: 18161149
[No Abstract] [Full Text] [Related]
31. [Anti-RANKL antibody for the treatment of rheumatoid arthritis].
Tanaka Y
Clin Calcium; 2011 Aug; 21(8):1223-9. PubMed ID: 21814029
[TBL] [Abstract][Full Text] [Related]
32. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD.
Lewiecki EM; Miller PD; McClung MR; Cohen SB; Bolognese MA; Liu Y; Wang A; Siddhanti S; Fitzpatrick LA;
J Bone Miner Res; 2007 Dec; 22(12):1832-41. PubMed ID: 17708711
[TBL] [Abstract][Full Text] [Related]
33. Denosumab.
Pageau SC
MAbs; 2009; 1(3):210-5. PubMed ID: 20065634
[TBL] [Abstract][Full Text] [Related]
34. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial.
Cohen SB; Dore RK; Lane NE; Ory PA; Peterfy CG; Sharp JT; van der Heijde D; Zhou L; Tsuji W; Newmark R;
Arthritis Rheum; 2008 May; 58(5):1299-309. PubMed ID: 18438830
[TBL] [Abstract][Full Text] [Related]
35. Increasing options for the treatment of osteoporosis.
Khosla S
N Engl J Med; 2009 Aug; 361(8):818-20. PubMed ID: 19671654
[No Abstract] [Full Text] [Related]
36. Denosumab, osteoporosis, and prevention of fractures.
Kiechl S; Willeit J; Schett G
N Engl J Med; 2009 Nov; 361(22):2188-9; author reply 2190-1. PubMed ID: 19940304
[No Abstract] [Full Text] [Related]
37. [New mechanism of action RANKL-antibodies reduce bone loss].
Kreutzkamp B
Med Monatsschr Pharm; 2006 Nov; 29(11):425-6. PubMed ID: 17131695
[No Abstract] [Full Text] [Related]
38. Osteoporosis drug licensed for women with high fracture risk.
Traynor K
Am J Health Syst Pharm; 2010 Jul; 67(13):1046. PubMed ID: 20554585
[No Abstract] [Full Text] [Related]
39. [RANKL inhibition as therapy for joint damage].
Akama H
Nihon Rinsho Meneki Gakkai Kaishi; 2007 Oct; 30(5):404-7. PubMed ID: 17984581
[TBL] [Abstract][Full Text] [Related]
40. Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies.
Reid IR; Miller PD; Brown JP; Kendler DL; Fahrleitner-Pammer A; Valter I; Maasalu K; Bolognese MA; Woodson G; Bone H; Ding B; Wagman RB; San Martin J; Ominsky MS; Dempster DW;
J Bone Miner Res; 2010 Oct; 25(10):2256-65. PubMed ID: 20533525
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
